Zacks Investment Research upgraded shares of Transcat (NASDAQ:TRNS) from a hold rating to a strong-buy rating in a research report sent to investors on Tuesday morning. They currently have $24.00 price target on the scientific and technical instruments company’s stock.
According to Zacks, “Transcat, Inc. distributes test and measurement instruments and provides accredited calibration services to a variety of industries including life sciences, pharmaceutical, petroleum refining, chemical manufacturing, public utility, pulp and paper, communications, automotive and aerospace. “
Separately, Singular Research boosted their target price on shares of Transcat from $25.00 to $30.00 and gave the stock a buy rating in a research report on Tuesday, August 21st.
TRNS stock opened at $22.99 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 2.04 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $149.11 million, a price-to-earnings ratio of 23.81, a price-to-earnings-growth ratio of 2.60 and a beta of 0.66. Transcat has a 12 month low of $12.15 and a 12 month high of $25.35.
Transcat (NASDAQ:TRNS) last posted its earnings results on Wednesday, October 24th. The scientific and technical instruments company reported $0.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.04. The company had revenue of $38.88 million during the quarter, compared to the consensus estimate of $38.00 million. Transcat had a net margin of 4.54% and a return on equity of 12.69%. On average, equities research analysts predict that Transcat will post 1 EPS for the current fiscal year.
In other Transcat news, Director John T. Smith sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 31st. The shares were sold at an average price of $10.30, for a total value of $30,900.00. Following the completion of the sale, the director now directly owns 42,166 shares of the company’s stock, valued at $434,309.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 10,639 shares of company stock valued at $109,307 over the last three months. Insiders own 8.80% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Transcat by 20.5% in the second quarter. BlackRock Inc. now owns 23,596 shares of the scientific and technical instruments company’s stock worth $446,000 after buying an additional 4,014 shares during the last quarter. Wedge Capital Management L L P NC lifted its stake in shares of Transcat by 32.1% in the third quarter. Wedge Capital Management L L P NC now owns 33,021 shares of the scientific and technical instruments company’s stock worth $755,000 after buying an additional 8,021 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Transcat by 2.8% in the first quarter. Dimensional Fund Advisors LP now owns 316,063 shares of the scientific and technical instruments company’s stock worth $4,946,000 after buying an additional 8,621 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of Transcat in the third quarter worth $235,000. Finally, Bailard Inc. acquired a new stake in shares of Transcat in the second quarter worth $196,000. Institutional investors and hedge funds own 54.77% of the company’s stock.
Transcat, Inc provides calibration and laboratory instrument services in North America and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.
Featured Story: Do You Need a Fiduciary?
Get a free copy of the Zacks research report on Transcat (TRNS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.